NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors

被引：0
作者：
Chang, Michael S. [1 ,2 ]
Said, Jordan T. [1 ,2 ]
Akama-Garren, Elliot H. [1 ,2 ]
Trepanowski, Nicole [2 ,3 ]
Bui, Ai-Tram N. [1 ,2 ]
Giobbie-Hurder, Anita [4 ]
Leboeuf, Nicole R. [1 ,2 ,5 ]
Hartman, Rebecca I. [1 ,2 ,6 ]
机构：
[1] Harvard Med Sch, BOSTON, MA USA
[2] Brigham & Womens Hosp, Dept Dermatol, 221 Longwood Ave, Boston, MA 02215 USA
[3] Boston Univ, Sch Med, Boston, MA USA
[4] Dana Farber Canc Inst, Dept Data Sci, Div Biostat, Boston, MA USA
[5] Dana Farber Brigham & Womens Canc Ctr, Ctr Cutaneous Oncol, Boston, MA USA
[6] Vet Integrated Serv Network VISN 1, Dept Dermatol, Jamaica Plain, MA USA
来源：
JAAD INTERNATIONAL | 2025年 / 18卷
基金：
美国国家卫生研究院;
关键词：
anti-PDL-1; atezolizumab; avelumab; cemiplimab; dAE; durvalumab; ICI; ipilimumab; melanoma; mutation; nivolumab; NRAS; pembrolizumab;
D O I：
10.1016/j.jdin.2024.11.004
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：165 / 167
页数：3
相关论文
共 50 条
  • [41] C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting
    Lauwyck, Justine
    Beckwee, Aline
    Santens, Arno
    Schwarze, Julia Katharina
    Awada, Gil
    Vandersleyen, Valerie
    Aspeslagh, Sandrine
    Neyns, Bart
    MELANOMA RESEARCH, 2021, 31 (04) : 371 - 377
  • [42] The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
    Dravillas, Caroline E.
    Coleman, Samuel S.
    Hoyd, Rebecca
    Caryotakis, Griffin
    Denko, Louis
    Chan, Carlos H. F.
    Churchman, Michelle L.
    Denko, Nicholas
    Dodd, Rebecca D.
    Eljilany, Islam
    Hardikar, Sheetal
    Husain, Marium
    Ikeguchi, Alexandra P.
    Jin, Ning
    Ma, Qin
    McCarter, Martin D.
    Osman, Afaf E. G.
    Robinson, Lary A.
    Singer, Eric A.
    Tinoco, Gabriel
    Ulrich, Cornelia M.
    Zakharia, Yousef
    Spakowicz, Daniel
    Tarhini, Ahmad A.
    Tan, Aik Choon
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (08): : 1978 - 1990
  • [43] A large scale meta analysis identifies common adverse events with checkpoint inhibitors vs chemotherapy in melanoma patients
    Zhang, Ruyi
    Li, Xuehui
    You, Zhiyu
    Jiang, Li
    Weng, Yaguang
    Shi, Qiong
    Du, Lin
    Yan, Shujuan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 74
  • [44] The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series
    Wen, Xizhi
    Ding, Ya
    Li, Jingjing
    Zhao, Jingjing
    Peng, Ruiqing
    Li, Dandan
    Zhu, Baoyan
    Wang, Yao
    Zhang, Xing
    Zhang, Xiaoshi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (09) : 1153 - 1162
  • [45] Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors
    Stuermer, Suzan H.
    Lechner, Axel
    Berking, Carola
    JOURNAL OF IMMUNOTHERAPY, 2021, 44 (05) : 193 - 197
  • [46] Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults
    Schonfeld, Sara J.
    Tucker, Margaret A.
    Engels, Eric A.
    Dores, Graca M.
    Sampson, Joshua N.
    Shiels, Meredith S.
    Chanock, Stephen J.
    Morton, Lindsay M.
    JAMA NETWORK OPEN, 2022, 5 (03)
  • [47] Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes
    Akturk, Halis Kaan
    Michels, Aaron W.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2020, 27 (04) : 187 - 193
  • [48] Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
    Simonaggio, Audrey
    Michot, Jean Marie
    Voisin, Anne Laure
    Le Pavec, Jerome
    Collins, Michael
    Lallart, Audrey
    Cengizalp, Geoffray
    Vozy, Aurore
    Laparra, Ariane
    Varga, Andrea
    Hollebecque, Antoine
    Champiat, Stephane
    Marabelle, Aurelien
    Massard, Christophe
    Lambotte, Olivier
    JAMA ONCOLOGY, 2019, 5 (09) : 1310 - 1317
  • [49] Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab
    Kethireddy, Nikhila
    Thomas, Steffi
    Bindal, Poorva
    Shukla, Prateek
    Hegde, Upendra
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (01) : 207 - 211
  • [50] Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors
    Hamamoto, Yasuo
    Shin, Natalya
    Hoshino, Tomohiro
    Kanai, Takanori
    FUTURE ONCOLOGY, 2018, 14 (30) : 3187 - 3198
12345